498 results on '"Poirier, John T."'
Search Results
2. Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer
3. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
4. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation
5. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
6. cfDNA methylome profiling for detection and subtyping of small cell lung cancers
7. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
8. Generation of hepatoma cell lines deficient in microsomal triglyceride transfer protein
9. ONECUT2 is a driver of neuroendocrine prostate cancer.
10. Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts
11. Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library
12. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer
13. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
14. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity
15. Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors
16. Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
17. TMEM41B Is a Pan-flavivirus Host Factor
18. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
19. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
20. Role of mTOR As an Essential Kinase in SCLC
21. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution
22. New Approaches to SCLC Therapy: From the Laboratory to the Clinic
23. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
24. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer
25. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics
26. Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts
27. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
28. A Genome-Wide Arrayed CRISPR Screen Reveals PLSCR1 as an Intrinsic Barrier to SARS-CoV-2 Entry
29. NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
30. Regenerative lineages and immune-mediated pruning in lung cancer metastasis
31. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
32. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
33. Peptide-based PET quantifies target engagement of PD-L1 therapeutics
34. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade inKEAP1mutant lung cancer
35. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
36. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer
37. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
38. Data from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
39. Data from Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
40. Table S2 from Lineage Reversion Drives WNT Independence in Intestinal Cancer
41. Supplementary Figures S1 - S5 from Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
42. Supplementary Figures from Lineage Reversion Drives WNT Independence in Intestinal Cancer
43. Data from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
44. Data from Lineage Reversion Drives WNT Independence in Intestinal Cancer
45. Supplementary Table 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
46. Supplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
47. Supplementary Fig 3 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
48. Supplementary Text from Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
49. Figure S3 from Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
50. Supplementary Fig 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.